Table 1.
Demographics and baseline disease characteristics (randomized patient dataset) for the MRI substudy
| Characteristic | DAPA+SAXA+MET (n = 46) | GLIM+MET (n = 36) | Total (N = 82) |
|---|---|---|---|
| Age, years | 58.9 (8.2) | 56.9 (10.0) | 58.0 (9.0) |
| Female, n (%) | 22 (47.8) | 19 (52.8) | 41 (50.0) |
| Weight, kg | 94.4 (16.5) | 90.9 (17.3) | 92.9 (16.8) |
| BMI, kg/m2 | 32.9 (4.7) | 32.3 (5.1) | 32.6 (4.9) |
| BMI group, kg/m2, n (%) | |||
| <25 | 1 (2.2) | 3 (8.3) | 4 (4.9) |
| ≥25– <27 | 4 (8.7) | 1 (2.8) | 5 (6.1) |
| ≥27– <30 | 11 (23.9) | 8 (22.2) | 19 (23.2) |
| ≥30 | 30 (65.2) | 24 (66.7) | 54 (65.9) |
| Race, n (%) | |||
| White | 46 (100.0) | 36 (100.0) | 82 (100.0) |
| Region, n (%) | |||
| Europe | 46 (100.0) | 36 (100.0) | 82 (100.0) |
| Duration of T2D, years | 6.4 (5.8) | 6.5 (6.4) | 6.4 (6.0) |
| HbA1c, % | 8.4 (0.8) | 8.6 (0.9) | 8.5 (0.9) |
| FPG, mg/dL | 10.2 (3.1) | 10.5 (2.6) | 10.4 (2.8) |
Abbreviations: BMI, body mass index; DAPA, dapagliflozin; FPG, fasting plasma glucose; GLIM, glimepiride; MET, metformin; MRI, magnetic resonance imaging; SAXA, saxagliptin; SD, standard deviation; T2D, type 2 diabetes.
All data are reported as mean (SD) unless specified otherwise. Includes all patients who consented to be in the MRI substudy.